Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory relapsed diffuse large B-cell lymphoma patients

Trial Details

NCT ID
NCT06651853
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab
Locations (sample)
  • Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

  • Written informed consent must be obtained before any trial-related procedures are implemented.
  • Participants must be aged 18 or older, of any gender, with an expected survival period of more than 3 months.
  • ECOG PS score must be between 0-3.
  • Participants must have histopathologically confirmed diffuse large B-cell lymphoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →